Hospital Miguel Servet -ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2017

  1. Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

    European Journal of Cancer, Vol. 75, pp. 73-82